NDA 021055 · Bausch
Targretin
Bexarotene · Oral · Retinoid
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Sep 14, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1999
Dec 29, 1999
Approved uses
2
Original approval plus efficacy supplements
Registered trials
46
9 Phase 3, 1 recruiting
FAERS reports
1,325
998 serious, 250 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: BIRTH DEFECTS TARGRETIN is a member of the retinoid class of drugs that is associated with birth defects in humans. Bexarotene also caused birth defects when administered orally to pregnant rats. TARGRETIN must not be administered to a pregnant woman. ( 8.1 ) WARNING: BIRTH DEFECTS See full prescribing information for complete boxed warning. TARGRETIN is a member of the retinoid class of drugs that is associated with birth defects in humans. Bexarotene also caused birth defects when administered orally to pregnant rats. TARGRETIN must not be administered to a pregnant woman. ( 8.1 )
What it is approved for
From the label in effect Apr 30, 2020.
TARGRETIN ® (bexarotene) Capsules are indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. TARGRETIN (bexarotene) is a retinoid indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. ( 1 )
Mechanism: Bexarotene selectively binds and activates retinoid X receptor subtypes (RXRα, RXRß, RXRγ). RXRs can form heterodimers with various receptor partners such as retinoic acid receptors (RARs), vitamin D receptor, thyroid receptor, and peroxisome proliferator activator receptors (PPARs). Once activated, these receptors function as transcription factors that regulate the expression of genes that control cellular differentiation and proliferation. Bexarotene inhibits the growth in vitro of some tumor cell lines of hematopoietic and squamous cell origin. It also induces tumor regression in vivo in...
Therapeutic areas: Ophthalmology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 29, 2015 Supplement 10 · Efficacy LabelLetter
- Dec 29, 1999 Original approval · Type 1 - New Molecular Entity · priority review LabelLetterReview
1 products under this application
- TARGRETIN · BEXAROTENE 75MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Bexarotene" as an intervention, any sponsor and status, largest first.
- Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung CancerPivotal-lookingCompleted
Eisai Inc.Eisai
NCT00050973 · 623 participants · Primary completion Nov 2004
Drug: bexarotene · For: Non-small Cell Lung Cancer
Sites: Birmingham, Alabama; Tucson, Arizona; Pasadena, California · 77 sites in all
- Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung CancerPivotal-lookingCompleted
Eisai Inc.Eisai
NCT00050960 · 612 participants · Start May 2002 · Primary completion Jul 2004
Drug: bexarotene with carboplatin and paclitaxel; carboplatin and paclitaxel · For: Non-small Cell Lung Cancer
Sites: Montgomery, Alabama; Tucson, Arizona; Concord, California · 154 sites in all
- Bexarotene in Treating Patients With Metastatic Breast CancerPivotal-lookingCompleted
Ligand PharmaceuticalsIndustry
NCT00003752 · 180 participants (planned) · Start Oct 1998
Drug: bexarotene · For: Breast Cancer
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 30 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT00425555 · 139 participants · Start Jan 2007 · Primary completion Jun 2013
Drug: Panobinostat · For: Cutaneous T-Cell Lymphoma
Sites: Birmingham, Alabama; Duarte, California; Los Angeles, California · 42 sites in all
- A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)Pivotal-lookingCompleted
Millennium Pharmaceuticals, Inc.Takeda (TAK)
NCT01578499 · 131 participants · Start Jun 11, 2012 · Primary completion May 31, 2016
Drug: Brentuximab Vedotin; Methotrexate and 1 more · For: Primary Cutaneous Anaplastic Large Cell Lymphoma; Mycosis Fungoides; Cutaneous T-Cell Lymphoma
Sites: Los Angeles, California; Palo Alto, California; Chicago, Illinois · 41 sites in all
- Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis FungoidesPivotal-lookingTerminated
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT00056056 · 93 participants · Start Jan 2003 · Primary completion May 2010
Drug: bexarotene; methoxypsoralen · For: Lymphoma
Sites: Graz, Austria; Vienna, Austria; Ghent, Belgium · 28 sites in all
- Bexarotene Augmentation of Antipsychotic Treatment for Chronic SchizophreniaPivotal-lookingCompleted
Beersheva Mental Health CenterGovernment (non-federal)
NCT00535574 · 90 participants · Start Nov 2008 · Primary completion Dec 2010
Drug: Bexarotene (Targretin LGD1069); bexarotene · For: Schizophrenia
Sites: Beersheba, Israel; Bat Yam, Israel; Hadera, Israel
Baylor Breast Care CenterAcademic, hospital or other
NCT00055991 · 87 participants · Start Sep 2001 · Primary completion Sep 2006
Drug: bexarotene · For: Breast Cancer
Sites: Washington D.C., District of Columbia; Houston, Texas; San Antonio, Texas · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective113
- off label use77
- death76
- hypothyroidism75
- hypertriglyceridaemia59
- disease progression58
- fatigue50
- pruritus47
- malignant neoplasm progression43
- condition aggravated39
- nausea37
- pneumonia34
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 12 |
| 2005 | 19 |
| 2006 | 28 |
| 2007 | 27 |
| 2008 | 28 |
| 2009 | 31 |
| 2010 | 31 |
| 2011 | 33 |
| 2012 | 30 |
| 2013 | 35 |
| 2014 | 33 |
| 2015 | 70 |
| 2016 | 73 |
| 2017 | 77 |
| 2018 | 87 |
| 2019 | 104 |
| 2020 | 97 |
| 2021 | 84 |
| 2022 | 115 |
| 2023 | 86 |
| 2024 | 75 |
| 2025 | 88 |
| 2026 | 61 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Targretin* (Bexarotene)
2024 spending
$4.9M
Beneficiaries
47
208 claims
Per beneficiary
$103,984
$272.73 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $24,085,741 |
| 2021 | $15,748,332 |
| 2022 | $13,367,911 |
| 2023 | $5,943,142 |
| 2024 | $4,887,241 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.
Horwitz SM, Scarisbrick JJ, Dummer R, et al. · Blood Adv 2021 · Clinical Trial, Phase III, Randomized Controlled Trial
- Interventions for mycosis fungoides.
Valipour A, Jäger M, Wu P, et al. · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Interventions for mycosis fungoides.
Weberschock T, Strametz R, Lorenz M, et al. · Cochrane Database Syst Rev 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United States.
Barta SK, Liu N, DerSarkissian M, et al. · Clin Lymphoma Myeloma Leuk 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- A phase II evaluation of bexarotene (Targretin) capsules in patients with metastatic melanoma.
Bedikian AY, Plager C, Papadopoulos N, et al. · Oncol Rep 2000 · Clinical Trial, Clinical Trial, Phase II
- Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study.
Dummer R, Prince HM, Whittaker S, et al. · Eur J Cancer 2020 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Bausch
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.